Böger R H, Bode-Böger S M, Szuba A, Tsao P S, Chan J R, Tangphao O, Blaschke T F, Cooke J P
Divisions of Cardiovascular Medicine, Clinical Pharmacology, Stanford University School of Medicine, Stanford, CA, USA.
Circulation. 1998 Nov 3;98(18):1842-7. doi: 10.1161/01.cir.98.18.1842.
Asymmetric dimethylarginine (ADMA) is an endogenous competitive inhibitor of nitric oxide (NO) synthase. Because endothelial NO elaboration is impaired in hypercholesterolemia, we investigated whether plasma concentrations of ADMA are elevated in young, clinically asymptomatic hypercholesterolemic adults. We further studied whether such elevation of ADMA levels was correlated with impaired endothelium-dependent, NO-mediated vasodilation and urinary nitrate excretion. In a randomized, double-blind, placebo-controlled study, we investigated whether these changes could be reversed with exogenous L-arginine.
We measured plasma levels of L-arginine, ADMA, and symmetrical dimethylarginine (SDMA) by high-performance liquid chromatography in 49 hypercholesterolemic (HC) and 31 normocholesterolemic (NC) humans. In 8 HC subjects, endothelium-dependent forearm vasodilation was assessed before and after an intravenous infusion of L-arginine or placebo and compared with 8 NC control subjects. ADMA levels were significantly elevated by >100% (2.17+/-0.15 versus 1.03+/-0.09 micromol/L; P<0.05) in HC subjects compared with NC adults. L-Arginine levels were similar, resulting in a significantly decreased L-arginine/ADMA ratio in HC subjects (27.7+/-2.4 versus 55. 7+/-5.4; P<0.05). In 8 HC subjects, intravenous infusion of L-arginine significantly increased the L-arginine/ADMA ratio and normalized endothelium-dependent vasodilation and urinary nitrate excretion. ADMA levels were inversely correlated with endothelium-mediated vasodilation (R=0.762, P<0.01) and urinary nitrate excretion rates (R=0.534, P<0.01).
We find that ADMA is elevated in young HC individuals. Elevation of ADMA is associated with impaired endothelium-dependent vasodilation and reduced urinary nitrate excretion. This abnormality is reversed by administration of L-arginine. ADMA may be a novel risk factor for endothelial dysfunction in humans.
不对称二甲基精氨酸(ADMA)是一氧化氮(NO)合酶的内源性竞争性抑制剂。由于高胆固醇血症患者的内皮NO生成受损,我们研究了临床无症状的年轻高胆固醇血症成年人血浆中ADMA浓度是否升高。我们进一步研究了ADMA水平的升高是否与内皮依赖性、NO介导的血管舒张受损及尿硝酸盐排泄有关。在一项随机、双盲、安慰剂对照研究中,我们研究了这些变化是否可以通过外源性L-精氨酸逆转。
我们采用高效液相色谱法测定了49例高胆固醇血症(HC)患者和31例正常胆固醇血症(NC)患者血浆中L-精氨酸、ADMA和对称二甲基精氨酸(SDMA)的水平。在8例HC患者中,静脉输注L-精氨酸或安慰剂前后评估内皮依赖性前臂血管舒张,并与8例NC对照患者进行比较。与NC成年人相比,HC患者的ADMA水平显著升高>100%(2.17±0.15对1.03±0.09μmol/L;P<0.05)。L-精氨酸水平相似,导致HC患者的L-精氨酸/ADMA比值显著降低(27.7±2.4对55.7±5.4;P<0.05)。在8例HC患者中,静脉输注L-精氨酸显著增加了L-精氨酸/ADMA比值,并使内皮依赖性血管舒张和尿硝酸盐排泄恢复正常。ADMA水平与内皮介导的血管舒张(R=0.762,P<0.01)和尿硝酸盐排泄率(R=0.534,P<0.01)呈负相关。
我们发现年轻HC个体中ADMA升高。ADMA升高与内皮依赖性血管舒张受损及尿硝酸盐排泄减少有关。给予L-精氨酸可逆转这种异常。ADMA可能是人类内皮功能障碍的一个新的危险因素。